01:19 , Oct 7, 2015 |  BC Extra  |  Company News

Management tracks

Neurology company Rodin Therapeutics Inc. (Cambridge, Mass.) named Adam Rosenberg CEO. Rosenberg was CEO of Teleos Therapeutics (Medford, Mass.). Oncology play Tracon Pharmaceuticals Inc. (NASDAQ:TCON) named Ronald Shazer CMO. Shazer was senior director and clinical...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Clinical News

AMA0076: Phase IIa started

Amakem began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 0.1%, 0.25% and 0.5% topical AMA0076 in about 80 patients. Amakem N.V. , Diepenbeek, Belgium   Product: AMA0076   Business: Ophthalmic   Molecular target:...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Clinical News

AMA0076: Phase IIa data

Top-line data from a double-blind, dose-escalation, U.S. Phase IIa trial in 82 patients with ocular hypertension or primary open-angle glaucoma showed that 0.3% topical AMA0076 eye drops significantly reduced mean diurnal IOP from baseline to...
07:00 , Mar 21, 2013 |  BC Innovations  |  Targets & Mechanisms

Understanding fibrosis

Researchers at The University of Alabama at Birmingham have identified idiopathic pulmonary fibrosis as a repurposing opportunity for fasudil, a Rho kinase inhibitor that Asahi Kasei Pharma Corp. markets as Eril to treat aneurysm. The...
08:00 , Mar 4, 2013 |  BC Week In Review  |  Company News

Devgen, Syngenta deal

Syngenta said that as of Feb. 26, 98.32% of agbio company Devgen shares had been tendered. Syngenta said following a "squeeze-out," the results of which will be announced on March 5, it will own 100%...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

Amakem, Flemish Agency for Innovation by Science and Technology autoimmune news

Amakem received an €1.4 million ($1.8 million) grant from the agency to use Amakem's localized drug action technology to discover and develop kinase inhibitor-based therapies to treat inflammatory bowel diseases (IBD). Amakem, which has already...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Clinical News

AMA0076: Phase IIa started

Amakem began a double-blind, placebo-controlled, dose-escalation, U.S. Phase IIa trial to evaluate topical AMA0076 eye drops in about 80 patients with ocular hypertension or primary open-angle glaucoma. Amakem N.V. , Diepenbeek, Belgium   Product: AMA0076...
07:00 , May 21, 2012 |  BC Week In Review  |  Company News

Amakem management update

Amakem N.V. , Diepenbeek, Belgium   Business: Ophthalmic   Hired: Steve Pakola as CMO, formerly CMO of ThromboGenics N.V.  ...
07:00 , May 21, 2012 |  BioCentury  |  Emerging Company Profile

Amakem: Switching off side effects

Amakem N.V. is using its localized drug action technology to reduce the side effects of treatments for ophthalmic diseases. The company hopes to establish proof of principle for the technology with a Rho kinase inhibitor...
07:00 , May 14, 2012 |  BC Week In Review  |  Clinical News

Amakem preclinical data

In rabbits, a single topical dose of 0.031-0.625% AMA0076 led to significant dose-dependent reductions in intraocular pressure (IOP) from baseline of 3.9-7 mmHg at 30 minutes and 4.6-7.5 mmHg at >=120 minutes vs. the vehicle-treated...